A reproduction of this study, correcting for the above concerns, would add significant value to the current literature. This would then allow clinicians to accurately assess risk factors for PGD in this instance and to counsel patients on the potential complications.

Christopher Jenks, MD
Askim Uysal, MD
Shreveport, LA

Affiliations: From the Department of Medicine and Pediatrics (Dr Jenks) and the Department of Pulmonary and Critical Care (Dr Uysal), Louisiana State University.

Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Correspondence to: Christopher Jenks, MD, 1501 Kings Highway, Shreveport, LA 71103; e-mail: cjjenks@lsuhsc.edu

© 2011 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).

DOI: 10.1378/chest.11-0682

REFERENCES


Response

To the Editor:

We appreciate the interest of Drs Jenks and Uysal in our article.1 We agree that not all the subjects with primary graft dysfunction (PGD) had a mean pulmonary arterial pressure (mPAP) > 25 mm Hg and that not all the subjects without PGD had an mPAP < 25 mm Hg. It was precisely for this reason that we presented our finding of a higher mPAP in patients with PGD than in those without as a continuous variable. The study was limited to patients with idiopathic pulmonary fibrosis, but not all patients with higher mPAP met the World Health Organization criteria for pulmonary hypertension, leading us to avoid the application of potentially inaccurate phenotypes. We do not have records of whether the subjects were actively being treated for pulmonary hypertension with pharmacologic agents.

Further, we agree that many factors may influence the first recorded pulmonary arterial pressure during the transplant procedure in patients with idiopathic pulmonary fibrosis. In order for intravascular volume or mechanical ventilation to account for our findings, patients at greater underlying risk for PGD would have to have more intravascular volume administered and higher levels of ventilator support before the diagnosis of PGD is made. Although this is unlikely, we see this as an opportunity for future research.

Jason D. Christie, MD, FCCP
Steven M. Kawut, MD, FCCP
Philadelphia, PA

Affiliations: From the Division of Pulmonary and Critical Care Medicine, University of Pennsylvania.

Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Kawut has received funding for consulting, speaking fees, conferences, travel to conferences, research, and serving on steering committees from Gilead, Actelion, United Therapeutics, Pfizer, Gerson Lehrman, and Clinical Advisors. Dr Christie has reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Correspondence to: Jason D. Christie, MD, FCCP, Division of Pulmonary and Critical Care Medicine, University of Pennsylvania, 719 Blockley Hall 423, Guardian Dr, Philadelphia, PA 19104-6021; e-mail: jchristi@mail.med.upenn.edu

© 2011 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).

DOI: 10.1378/chest.11-1228

REFERENCES


Flavoxocid and Hypersensitivity Pneumonitis

To the Editor:

I have just become aware of the report in CHEST (October 2010) by Youssef and Tomic1 of a case of hypersensitivity pneumonitis

associated with the use of our product, Limbrel (flavocoxid). I wish to thank them for their clear and concise description of the clinical presentation and appropriate treatment of this rare event.

Limbrel was first marketed nationally in April 2004. At that time, no instances of hypersensitivity pneumonitis had been reported in clinical trials or test marketing surveillance. By 2008, three cases had been reported, and the package insert was revised to reflect this complication. At the time of its most recent revision, in mid-2010, the package insert was again revised to reflect seven confirmed cases reported in post-marketing surveillance and through the US Food and Drug Administration’s MedWatch. As of that time, approximately 270,000 people had been exposed to the product as judged by the number of new prescriptions filled. Thus, the apparent incidence of hypersensitivity pneumonitis, as nearly as we can estimate it, is approximately 0.0023%, or somewhere around two to three per 100,000.

Given such a low incidence, it is unlikely that any individual physician would encounter the problem. The report by Youssef and Tomic should increase awareness of this rare event and enable more rapid institution of appropriate therapy and avoidance of unnecessary and inappropriate treatments.

Robert M. Levy, MD
Scottsdale, AZ

Affiliations: From Primus Pharmaceuticals, Inc.
Financial/nonfinancial disclosures: The author has reported to CHEST the following conflicts of interest: Dr Levy is Director of Clinical Development for Primus Pharmaceuticals, Inc; the manufacturer of Limbrel.
Correspondence to: Robert Levy, MD, Primus Pharmaceuticals, Inc, 4725 N Scottsdale Rd, Ste 200, Scottsdale, AZ 85251; e-mail: rlevy@primusrx.com
© 2011 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).
DOI: 10.1378/chest.11-0632

REFERENCES


Response

To the Editor:

We appreciate the comments from Dr Robert Levy about our case presentation. First, we would like to applaud the pharmaceutical company for their efforts in careful monitoring of published literature concerning their products. It is encouraging that their safety packets are regularly updated to reflect new reports of possible side effects.

Hypersensitivity pneumonitis represents a complex pulmonary disorder of varying intensity and clinical presentation, which is characterized by a diffuse Tc1 immune response of lung parenchyma in patients previously sensitized to one of >300 causative agents that may favor the hypersensitivity pneumonitis reaction. It remains an elusive diagnosis that is achieved by performing clinical, radiologic, physiologic, and immunologic evaluations. Hypersensitivity pneumonitis is known to be caused by a large number of different medications. This possible side effect can go unnoticed and misdiagnosed if physicians do not report their experiences. Possible consequences can include many unnecessary procedures that can cause an increase in morbidity and mortality for the patients.

The purpose of our case presentation was to bring to light a possible, though rare, side effect that patients may experience when their doctors administer flavocoxid (Limbrel). Increasing the awareness of yet another possible cause of hypersensitivity pneumonitis will help physicians to reach the right diagnosis and avoid unnecessary and potentially harmful diagnostic procedures.

Also, it will be useful to review all published reports of flavocoxid causing hypersensitivity pneumonitis in order to assess the common characteristics among these patients that could have predisposed them to hypersensitivity pneumonitis. This will help us to identify groups of patients who should avoid flavocoxid. We believe that our report will help physicians and increase the awareness of this rare but possible cause of hypersensitivity pneumonitis.

John G. Youssef, MD
Rade Tomic, MD
Milwaukee, WI

Affiliations: From the Department of Pulmonary Medicine, Medical College of Wisconsin.
Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Correspondence to: John G. Youssef, MD, Department of Pulmonary Medicine, 9200 W Wisconsin Ave, Milwaukee, WI 53226; e-mail: jyoussef@mcw.edu
© 2011 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).
DOI: 10.1378/chest.11-0982

REFERENCES


Can Pulmonary Arterial Hypertension Be Diagnosed by an Elevated Pulmonary Capillary Wedge Pressure Outside of the Guideline Criteria?

To the Editor:

We read with interest the report by Frost and colleagues1 in a recent issue of CHEST (July 2011) comparing the results of the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL Registry) with the other registries of pulmonary arterial hypertension (PAH). We are troubled by the inclusion of patients with a pulmonary capillary wedge pressure (PCWP) > 15 mm Hg, a value > 2 SD higher...